Core Insights - Skye Bioscience, Inc. reported financial results for Q4 and full year 2025, highlighting advancements in its clinical programs targeting obesity and related conditions [1][14]. Financial Performance - As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $25.7 million, expected to fund operations through Q4 2026 [14]. - R&D expenses for Q4 2025 were $11.5 million, up from $7.8 million in Q4 2024, primarily due to manufacturing costs for the anticipated Phase 2b trial [15]. - For the full year 2025, R&D expenses reached $42.4 million, compared to $18.7 million in 2024, driven by clinical study and manufacturing costs [16]. - G&A expenses for Q4 2025 were $3.4 million, down from $4.6 million in Q4 2024, mainly due to reduced stock-based compensation and professional services [17]. - The net loss for Q4 2025 was $14.4 million, compared to $9.7 million in Q4 2024, with a full-year net loss of $55.9 million, significantly higher than the $26.6 million loss in 2024 [20][21]. Clinical Developments - The CBeyond Expansion Study initiated higher-dose evaluations of nimacimab, with cohorts receiving 400 mg and 600 mg IV doses, aiming to generate safety and pharmacokinetic data [6][7]. - Interim results from the Phase 2a trial showed a 22.3% mean weight loss at 52 weeks for the nimacimab plus semaglutide combination, with no plateau observed [12]. - The combination therapy demonstrated a statistically significant improvement in lean-to-fat mass ratio and waist circumference, with a lower weight regain during the follow-up period compared to semaglutide alone [12]. Upcoming Milestones - Skye plans to present preclinical data in Q2 2026 and finalize the Phase 2b study design by Q4 2026, with topline results from the CBeyond Expansion Study expected in the same quarter [13][18]. Research and Development Highlights - Skye is advancing its antibody-peptide conjugate (APC) program, which combines nimacimab's mechanism with a GLP-1 receptor agonist for enhanced therapeutic effects [12]. - The company is also working on optimizing manufacturing processes to support the anticipated Phase 2b trial and improve cost efficiency [11]. Company Overview - Skye Bioscience focuses on developing next-generation molecules targeting G-protein-coupled receptors for metabolic health, with nimacimab being a key candidate in its pipeline [23].

Core Insights - Skye Bioscience, Inc. has completed the treatment phase for the last patient in its Phase 2a CBeyond™ clinical trial evaluating nimacimab for obesity, with topline data expected in late Q3/early Q4 of 2025 [1][3] Group 1: Clinical Trial Details - The CBeyond™ Phase 2a trial is a randomized, double-blind, placebo-controlled study focusing on weight loss, safety, tolerability, and metabolic biomarkers in adults with obesity and overweight [2] - The primary endpoint of the trial is to compare weight change from baseline to 26 weeks between nimacimab and placebo [2] - An exploratory arm of the trial is assessing the combination of semaglutide (Wegovy®) with nimacimab versus semaglutide with placebo [2] Group 2: Study Progress and Future Plans - Skye has completed enrollment for a 26-week extension of the Phase 2a trial, which aims to provide data on 52 weeks of treatment with nimacimab, either as monotherapy or in combination with semaglutide [5] - Patients who completed the initial 26 weeks were eligible for the extension, potentially leading to a total treatment duration of 52 weeks followed by a 12-week follow-up [5] - Data from the extension study is expected to be reported in Q1 2026 [5] Group 3: Company Strategy and Market Context - Skye is focused on developing new therapeutic pathways for metabolic health, particularly through the modulation of G-protein coupled receptors [6] - The company believes that peripheral CB1 inhibition via an antibody presents a promising alternative to existing GLP-1 weight loss drugs, which may not meet all patients' needs [4] - Skye aims to advance nimacimab as a potential new therapeutic option for obesity and overweight, addressing limitations of current treatments [4]